GlassScriptPhysician profile
Derek Srouji
NPI 1003376880
$6,014.75
in general payments reported to CMS, 2019-2025
24 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $956 · 2023: $1,410 · 2024: $1,759 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,670 · Education: $161 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,670.19 |
| Education | $161.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,581.69 | 2022-2025 | General - Therapies, Avvigo Guidance System, Eluvia |
| Abiomed | $1,245.39 | 2025 | |
| Abbott Laboratories | $390.46 | 2024 | Cardiomems, Mitraclip, Gallant |
| Stryker Corporation | $265.70 | 2025 | Flowtriever, Clottriever Bold Catheter |
| Philips North America LLC | $207.82 | 2021-2024 | (Ck4) Mcot |
| Atricure, INC. | $202.03 | 2024 | |
| Medtronic, INC. | $161.49 | 2024 | Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.70 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $141.86 | 2024 | |
| Inari Medical, INC. | $139.65 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Chiesi USA, INC. | $125.22 | 2023 | Kengreal |
| Merck Sharp & Dohme LLC | $76.06 | 2022-2024 | Verquvo |
| Shockwave Medical, INC | $55.79 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Baxter Healthcare | $55.36 | 2025 | Perclot |
| Astrazeneca Pharmaceuticals LP | $42.65 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $33.29 | 2022 | |
| Depuy Synthes Sales INC. | $24.55 | 2025 | |
| Esperion Therapeutics, INC. | $22.00 | 2024 | Nexletol |
| Amgen INC. | $19.40 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.34 | 2024 | |
| Pylant Medical | $17.73 | 2022 | |
| Novo Nordisk INC | $17.73 | 2024 | Ozempic |
| Abbvie INC. | $13.03 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Srouji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.